Measuring ENPP1, cGAS and FAP proteins in stored tumor samples from Vietnam
Examines ENPP1, cGAS and FAP proteins in archived tumor samples from several cancers.
Key facts
- Who runs it
- Tam Anh Research Institute
- Where
- Hanoi and Ho Chi Minh City, VietnamSee the 2 sites
- Trial code
- Registry title
- ENPP1/cGAS (EG) and FAP Expression Profiles in Solid Tumors: An Immunohistochemical Study in a Vietnamese Cohort
- Status
- Recruiting
- People taking part
- 162 people, planned
- Started
- 19 Mar 2026
- Expected to end
- 30 Jun 2027
- Type of study
- Observational
- Treatments tested
- IHC analysis for ENPP1, cGAS, and FAP expression
- Record updated
- 26 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The study looks at stored tumor tissue samples from Vietnamese adults with solid cancers. No new procedures are done on patients.
- Age
- 18 years or older at the time the tumor tissue was collected
- Sex
- All sexes
- Disease stage
- A solid cancer confirmed under the microscope, for example colorectal, liver, lung, melanoma, pancreatic or breast cancer
- Biomarker or test result
- Stored tumor samples are tested for ENPP1, cGAS and FAP protein levels
Main reasons for not taking part
- The medical record diagnosis does not agree with the tissue findings
- The patient or their representative declined use of the tissue for research
- Institutional rules or the ethics committee do not allow research use of the sample
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- Confirmed diagnosis: Patients with a histopathologically or cytologically confirmed diagnosis of malignant solid tumors, including but not limited to colorectal cancer (CRC), hepatocellular carcinoma (HCC), lung cancer, melanoma, pancreatic cancer,breast cancer, or other solid tumors relevant to the study objectives
- Age: Vietnamese patients aged ≥ 18 years at the time of tumor tissue collection
- Availability and quality of biospecimens:; Availability of formalin-fixed, paraffin-embedded (FFPE) tumor tissue specimens collected within 24 months prior to specimen eligibility verification and currently stored at the study site; Tumor tissue specimens confirmed by a study pathologist to contain an adequate proportion of viable tumor cells (minimum of 1500 tumor cells per section) and sufficient material for analysis (at least one FFPE block or four unstained slides, 3-5 um in thickness); Only archived residual tissue specimens remaining after completion of all routine clinical diagnostic and/or therapeutic purposes will be used for study purposes
- Availability of clinical data: Patient medical records must contain essential baseline information required for the study, including at minimum basic demographic data (age, sex) and histopathological diagnosis
- Ethical considerations: The study will be conducted using tissue specimens classified as archived samples at the time of eligibility assessment and is eligible for a waiver of informed consent in accordance with the requirements and approval of the Local Ethics Committee/Institutional Review Board (LEC/IRB)
Who cannot take part
- Discordance between clinical diagnosis and tissue histopathology: The diagnosis documented in the medical record is inconsistent with the histopathological findings of the tissue specimen intended for study use
- Legal or policy restrictions: Patients or their legally authorized representatives have declined the use of tissue specimens for secondary research purposes, or the specimens are not permitted for research use under institutional policies or decisions of the LEC/IRB
Where in Vietnam
- Tam Anh General HospitalHanoi, VietnamContact: Dung T Trinh, MD, PhDTaking people
- Tam Anh TP. Ho Chi Minh HospitalHo Chi Minh City, VietnamContact: Tung N Tran, MD, MsCTaking people
About the trial
What the trial wants to find out
This Vietnam-based observational study examines ecto-nucleotide pyrophosphatase/phosphodiesterase 1/cyclic GMP-AMP synthase (ENPP1/cGAS) protein and stromal fibroblast activation protein (FAP) expression in multiple solid tumor samples using immunohistochemistry (IHC). The study involves no investigational treatments or participant-facing procedures. Tumor samples used in this study consist exclusively of archived formalin-fixed paraffin- embedded (FFPE) tumor samples that were collected as part of routine clinical diagnosis or treatment and for which all required procedures for standard clinical care have been completed. Only archived tumor samples obtained from routine clinical care will be included in this study. No additional biopsy, surgical resection, or specimen collection will be performed for research purposes, and no sample will be diverted prior to completion of clinical requirements. All included archived tumor samples will undergo ENPP1, cGAS, and FAP IHC analysis according to the procedures specified in the Laboratory Manual.
The group in the trial
- Patients with malignant solid tumors
Patients with a histopathologically or cytologically confirmed diagnosis of malignant solid tumors, including but not limited to colorectal cancer (CRC), hepatocellular carcinoma (HCC), lung cancer, melanoma, pancreatic cancer, breast cancer, or other solid tumors whose tumor tissue samples are analyzed for ENPP1/cGAS (EG) and FAP Expression
Treatment: IHC analysis for ENPP1, cGAS, and FAP expression
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- ENPP1/cGAS (EG) and FAP Expression Profiles in Solid Tumors: An Immunohistochemical Study in a Vietnamese Cohort
- Plain-language title
- Measuring ENPP1, cGAS and FAP proteins in stored tumor samples from VietnamGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 26 October 2026